Israeli biopharmaceutical firm BioLineRx has launched a Phase Ib/II clinical trial (BATTLE) of BL-8040 in combination with Genentech’s anti-PDL1 immunotherapy atezolizumab (Tecentriq) in patients suffering from acute myeloid leukaemia (AML).

BL-8040 is a short peptide, high-affinity antagonist of CXCR4 chemokine receptor reported to be involved in tumour progression, angiogenesis, metastasis and cell survival.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The multi-centre, single arm, open-label BATTLE trial will investigate the safety, tolerability, relapse-free survival and minimal residual disease status of the combination as a maintenance treatment.

Approximately 60 intermediate and high-risk patients who experienced a complete response (CR) after treatment with induction and consolidation therapy will be enrolled into the trial.

“We are hopeful that combining atezolizumab with BL-8040 will demonstrate the potential to establish a new treatment for AML patients that would extend the duration of remission following induction treatment.”

BioLineRx CEO Philip Serlin said: “The BATTLE study is the first study under our collaboration in hematologic malignancies, and we are hopeful that combining atezolizumab with BL-8040 will demonstrate the potential to establish a new treatment for AML patients that would extend the duration of remission following induction treatment, in particular for patients for whom stem-cell transplantation is inappropriate.”

Planned to be conducted at 22 sites in the US, Europe and Israel, the trial’s primary endpoint is assessment of the combination’s ability to prolong relapse-free survival.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The impact of the therapy on minimal residual disease, various immunological parameters and potential biomarkers will also be monitored.

In September last year, BioLineRx and Genentech entered cancer immunotherapy collaboration to evaluate the combination in different Phase Ib/II trials for various types of cancer.

Under this partnership, the firms intend to launch additional combination trials by the end of this year.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact